Pharbaco Central Pharmaceutical Joint Stock Co No.1
UUPCOM:PBC5,200.00
VND
0.00
(0.00%)
ISIN
VN000000PBC6
Return %
Stock
S&P 500
1Y
-10.34
14.20
3Y
-50.94
81.12
5Y
-71.74
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Sector
- Distribution services
- Industry
- Medical distributors
- Address
- Ha Noi Vietnam
- IPO Date
- Nov 26, 2019
- Website
- pharbaco.com.vn
- Similar Companies
- Business
- Pharbaco Central Pharmaceutical Joint Stock Company No. 1 is a Vietnam-based pharmaceutical manufacturing company primarily engaged in the research, development, production, and distribution of generic and branded prescription drugs, over-the-counter medicines, and healthcare products. The company operates through extensive therapeutic and formulation segments comprising beta-lactam antibiotics, including penicillins and cephalosporins; non-beta-lactam medications; cardiovascular agents; anti-tuberculosis and antimalarial treatments; analgesics and antipyretics; gastrointestinal therapies; vitamins, minerals, and dietary supplements; and oncology therapeutics. Its manufactured dosage forms include solid oral dosages, such as uncoated, film-coated, and sugar-coated tablets, effervescent tablets, and hard and soft gelatin capsules; liquid and sterile formulations, including powder for injection, lyophilized injectables, liquid ampoules, eye and ear drops, oral solutions, and suspensions; and large-volume infusion solutions. Additionally, the company provides pharmaceutical contract manufacturing (CMO) services, packaging, quality control testing, and warehousing and distribution services. Pharbaco distributes its products across Vietnam to public and private healthcare facilities, retail pharmacies, and institutional channels, while exporting finished pharmaceuticals to international markets across Asia, Africa, and Eastern Europe. In recent operational developments, the company has advanced the implementation of its multi-phase manufacturing modernization program at its production facility in Soc Son District, Hanoi, constructing and upgrading advanced manufacturing lines to European Union Good Manufacturing Practice (EU-GMP) and WHO-GMP standards for sterile injectables and solid oral dosages to target top-tier hospital tender groups and expand international export compliance. Concurrently, the company has implemented corporate governance reorganizations, executive leadership and board transitions, and balance sheet and capital restructuring measures to optimize operational efficiency and sustain production scale. Founded in 1954 and equitized in 2007, Pharbaco Central Pharmaceutical Joint Stock Company No. 1 is headquartered in Hanoi, Vietnam, and trades on the UPCoM exchange under the ticker PBC.